MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is an Australian AI company that is pioneering acoustic biomarker technology that transforms human voice into actionable health intelligence.
Voice is a remarkable diagnostic marker for internal health and disease. The company's proprietary algorithms analyze over 50 million data points with 140 acoustic parameters extracted from human speech, including fundamental frequency variations, spectral entropy, jitter, shimmer, and harmonic-to-noise ratios — to identify physiological states with incredible clinical-grade precision.
The Science of Acoustic Biomarkers
Human voice contains rich biometric data invisible to the human ear but detectable through advanced signal processing.
MindBio's AI decodes these acoustic signatures to reveal physiological states and does it with unprecedented precision.
Why Voice is the Ultimate Non-Invasive Biomarker
The human voice is produced through a complex neuromuscular system involving the respiratory system, larynx, and articulators.
Any substance affecting the central nervous system — alcohol, drugs, fatigue — inevitably manifests in measurable vocal changes.
Unlike blood tests or breathalyzers, voice analysis is completely non-invasive, requires no specialized equipment, and can be performed remotely, making it ideal for scalable workforce monitoring and telehealth applications.
MindBio Appoints National Drug Policy & Mining Industry Expert to Lead South American Mining Industry Commercialization – Feb 24, 2026
To view this news, please click here.
Some Key Charts
AI stocks are bottoming, and flashing buy signals, basis this AI stocks ETF chart (AIQ).
Note the massively oversold MACD indicator and the exciting position of the Stochastics (14,7,7 series) and RSI oscillators.
AI stocks are bottoming, and MindBio leads the pack.
On this exciting daily chart, a bull wedge breakout is in play, volume is surging, and there's a bullish cross of the key 10,30 moving averages.
The stock is already leading the AIQ; MindBio is already up about 100% from its early March low, while the AIQ is only bottoming now.
Meet Booze AI
The world's first voice-activated AI-powered blood alcohol test on a smartphone.
Customers get instant estimates of their BAC and see how alcohol affects their performance.
Zero-Tolerance Industries Zero-Compromise Safety
MindBio brings purpose-built hardware-software solutions for scalable, on-site drug and alcohol intoxication screening in zero-tolerance regulated industries.
The Challenge: Traditional Testing Falls Short
- The Problem: Breathalyzers require physical presence.
- The MindBio Solution: Voice testing works from any location.
- The Problem: Lab tests take days for results.
- The MindBio Solution: Voice analysis completes in seconds.
- The Problem: Random testing creates scheduling chaos.
- The MindBio Solution: Continuous monitoring without disruption.
- The Problem: Equipment maintenance is costly.
- The MindBio Solution: Edge AI Hardware-Software Solutions for scalable remote deployment, low cost.
Edge AI Voice-Initiated Drug & Alcohol Intoxication Detection Kiosks
How AI is Reshaping Telehealth
Artificial intelligence is addressing the fundamental limitations of remote healthcare by enabling objective, continuous health assessment without physical examination. Voice analysis represents the most accessible and scalable form of AI-powered diagnostics.
Traditional telehealth relies heavily on patient self-reporting and visual observation. Voice biomarker technology adds an entirely new dimension—extracting clinically relevant data from natural speech patterns that patients cannot consciously manipulate or misrepresent.
Voice-Based Intoxication Detection
MindBio's core competency lies in detecting substance impairment through voice analysis; it's a capability with profound implications for telehealth, workplace safety, and public health.
The Science of Detection
Alcohol and drugs affect the neuromuscular systems responsible for speech production in predictable, measurable ways.
AI models are trained to identify these acoustic signatures with clinical-grade accuracy.
Fresh News
MindBio Announces Upsize to Private Placement up to $1.5 million – March 19, 2026
To view the news, please click here.
Shares Outstanding
MindBio Therapeutics Corp. has approximately 4.79 million common shares issued and outstanding.
Significant Shareholders
Key individuals holding shares include CEO Justin Hanka and Director Gavin Upiter.
Big Name Brokers Involved
Stock Price March 31, 2026: CA$1.25
Short-Term Technical Price Target: CA$1.70
Medium-Term Technical Price Target: CA$3.00
Long-Term Technical Price Target: CA$6.00
Technical Rating: Strong Speculative Buy
The company's latest investor presentation is here.
| Want to be the first to know about interesting Medical Devices and Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Mindbio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
-
For this article, Mindbio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
- Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
- Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company.
For additional disclosures, please click here.
